Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease

Experimental Neurology

Volumn 228, Issue 1, 2011, Pages 99-108

  Voutilainen, Merja H ^a   Bäck, Susanne ^a   Peränen, Johan ^b   Lindholm, Päivi ^b   Raasmaja, Atso ^a   Männistö, Pekka T ^a   Saarma, Mart ^b   Tuominen, Raimo K ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

6 OHDA; CDNF; Chronic infusion; GDNF; MANF; RAT

Indexed keywords

AMPHETAMINE; CEREBRAL DOPAMINE NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; IODINE 125; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; BRAIN NERVE CELL; CHRONIC DRUG ADMINISTRATION; CIRCLING BEHAVIOR; CONTINUOUS INFUSION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG TRANSPORT; IMMUNOREACTIVITY; ISOTOPE LABELING; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; HUMANS; INFUSION PUMPS; MALE; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR;

EID: 79851509373     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.12.013     Document Type: Article

References (42)

1. Apostolou A., Shen Y., Liang Y., Luo J., Fang S. Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp. Cell Res. 2008, 314:2454-2467.
2. Björklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 1997, 4:186-200.
3. Connor B., Kozlowski D.A., Schallert T., Tillerson J.L., Davidson B.L., Bohn M.C. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 1999, 12:1936-1951.
4. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
5. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
6. Gyárfás T., Knuuttila J., Lindholm P., Rantamäki T., Castrén E. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell Mol Neurobiol. 2010, 3:361-368.
7. Hellman M., Arumäe U., Yu L.-Y., Lindholm P., Peränen J., Saarma M., Permi P. Neurotrophic factor MANF has a unique mechanism to rescue apoptotic neurons. J. Biol. Chem. 2011, 286:2675-2680.
8. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., Lin L.F., Gerhardt G.A. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett. 1994, 182:107-111.
9. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., Kirik D., Moffat B., Simmons L., Johnson E., Milbrandt J., Rosenthal A., Björklund A., Vandlen R.A., Hynes M.A., Phillips H.S. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 1998, 18:4929-4937.
10. Hou J.G., Lin L.F., Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J. Neurochem. 1996, 66:74-82.
11. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 1995, 672:104-111.
12. Kearns C.M., Cass W.A., Smoot K., Kryscio R., Gash D.M. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J. Neurosci 1997, 17:7111-7118.
13. Kirik D., Rosenblad C., Björklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 2000, 12:3871-3882.
14. Kirik D., Georgievska B., Rosenblad C., Björklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci. 2001, 13:1589-1599.
15. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
16. Lapchak P.A., Jiao S., Collins F., Miller P.J. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res. 1997, 747:92-102.
17. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
18. Lindholm P., Saarma M. Novel CDNF/MANF family of neurotrophic factors. Dev. Neurobiol. 2010, 70:360-371.
19. Lindholm P., Peränen J., Andressoo J.O., Kalkkinen N., Kokaia Z., Lindvall O., Timmusk T., Saarma M. MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol. Cell. Neurosci. 2008, 39:356-371.
20. Lindholm P., Voutilainen M.H., Lauren J., Peränen J., Leppänen V.M., Andressoo J.O., Lindahl M., Janhunen S., Kalkkinen N., Timmusk T., Tuominen R.K., Saarma M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
21. Misasi R., Garofalo T., Di Marzio L., Mattei V., Gizzi C., Hiraiwa M., Pavan A., Grazia Cifone M., Sorice M. Prosaposin: a new player in cell death prevention of U937 monocytic cells. Exp. Cell Res. 2004, 298:38-47.
22. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., Lozano A.M., Penn R.D., Simpson R.K., Stacy M., Wooten G.F. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
23. O'Brien J.S., Carson G.S., Seo H.C., Hiraiwa M., Kishimoto Y. Identification of prosaposin as a neurotrophic factor. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9593-9596.
24. Oiwa Y., Yoshimura R., Nakai K., Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res. 2002, 947:271-283.
25. Palgi M., Lindström R., Peränen J., Piepponen T.P., Saarma M., Heino T.I. Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2429-2434.
26. Parkash V., Lindholm P., Peränen J., Kalkkinen N., Oksanen E., Saarma M., Leppänen V.M., Goldman A. The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Eng. Des. Sel. 2009, 22:233-241.
27. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic, San Diego.
28. Piltonen M., Bespalov M.M., Ervasti D., Matilainen T., Sidorova Y.A., Rauvala H., Saarma M., Männistö P.T. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp. Neurol. 2009, 219:499-506.
29. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 1999, 11:1554-1566.
30. Runeberg-Roos P., Virtanen H., Saarma M. RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface. Oncogene 2007, 26:7909-7915.
31. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., Gerhardt G.A., Gash D.M. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol. 2006, 202:497-505.
32. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
33. Shults C.W., Kimber T., Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport 1996, 7:627-631.
34. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102:216-222.
35. Tadimalla A., Belmont P.J., Thuerauf D.J., Glassy M.S., Martindale J.J., Gude N., Sussman M.A., Glembotski C.C. Mesencephalic astrocyte-derived neurotrophic factor is an ischemia-inducible secreted endoplasmic reticulum stress response protein in the heart. Circ. Res. 2008, 103:1249-1258.
36. Tomac A., Widenfalk J., Lin L.F., Kohno T., Ebendal T., Hoffer B.J., Olson L. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8274-8278.
37. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
38. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24:485-493.
39. Voutilainen M.H., Bäck S., Pörsti E., Toppinen L., Lindgren L., Lindholm P., Peränen J., Saarma M., Tuominen R.K. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J. Neurosci. 2009, 29:9651-9659.
40. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 1991, 231:482-497.
41. Yu L.Y., Jokitalo E., Sun Y.F., Mehlen P., Lindholm D., Saarma M., Arumäe U. GDNF-deprived sympathetic neurons die via a novel nonmitochondrial pathway. J. Cell Biol. 2003, 163:987-997.
42. Zhang Z., Miyoshi Y., Lapchak P.A., Collins F., Hilt D., Lebel C., Kryscio R., Gash D.M. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther. 1997, 282:1396-1401.